Short answer
ENANTA PHARMACEUTICALS INC (ENTA) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal quarter and full-year results for period ended September 30, 2026.
ENANTA PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal quarter and full-year results for period ended September 30, 2026
- Press release contains the substantive financial results and management commentary as Exhibit 99.1
- Investor focus: quarterly performance, cash position, pipeline progress, and outlook for Enanta’s drug-development programs
Item EX-99.1 · Exhibit EX-99.1
- Revenue $63.0M in fiscal 2026, down from $65.3M, reflecting declining AbbVie MAVYRET/MAVIRET royalties
- Cash and marketable securities $194.5M, with retained royalties expected to fund operations into fiscal 2029
- Zelicapavir pediatric LOTUS enrollment complete, with topline data expected in 1Q 2027
- RESOLVE adult high-risk RSV trial dosing initiated, with Phase 2b data expected in 2027
- CEO Jay Luly retiring by February 1, 2027, while workforce reductions of approximately one-third target greater operating efficiency
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ENANTA PHARMACEUTICALS INC 8-K filings
Get the next ENTA 8-K as it lands
Follow ENTA for push alerts, or ask the research agent what this filing means.